nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Convulsion—Vincristine—colon cancer	0.00239	0.00239	CcSEcCtD
Gadoversetamide—Hypertension—Vincristine—colon cancer	0.00238	0.00238	CcSEcCtD
Gadoversetamide—Loss of consciousness—Irinotecan—colon cancer	0.00236	0.00236	CcSEcCtD
Gadoversetamide—Myalgia—Vincristine—colon cancer	0.00235	0.00235	CcSEcCtD
Gadoversetamide—Cough—Irinotecan—colon cancer	0.00235	0.00235	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Capecitabine—colon cancer	0.00233	0.00233	CcSEcCtD
Gadoversetamide—Hypertension—Irinotecan—colon cancer	0.00232	0.00232	CcSEcCtD
Gadoversetamide—Pneumonia—Capecitabine—colon cancer	0.00232	0.00232	CcSEcCtD
Gadoversetamide—Discomfort—Irinotecan—colon cancer	0.00226	0.00226	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Vincristine—colon cancer	0.00225	0.00225	CcSEcCtD
Gadoversetamide—Oedema—Vincristine—colon cancer	0.00225	0.00225	CcSEcCtD
Gadoversetamide—Conjunctivitis—Capecitabine—colon cancer	0.00224	0.00224	CcSEcCtD
Gadoversetamide—Urinary tract infection—Capecitabine—colon cancer	0.00224	0.00224	CcSEcCtD
Gadoversetamide—Convulsion—Fluorouracil—colon cancer	0.00223	0.00223	CcSEcCtD
Gadoversetamide—Confusional state—Irinotecan—colon cancer	0.00221	0.00221	CcSEcCtD
Gadoversetamide—Nervous system disorder—Vincristine—colon cancer	0.00221	0.00221	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Vincristine—colon cancer	0.00221	0.00221	CcSEcCtD
Gadoversetamide—Haematuria—Capecitabine—colon cancer	0.0022	0.0022	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Irinotecan—colon cancer	0.0022	0.0022	CcSEcCtD
Gadoversetamide—Oedema—Irinotecan—colon cancer	0.0022	0.0022	CcSEcCtD
Gadoversetamide—Chest pain—Fluorouracil—colon cancer	0.00219	0.00219	CcSEcCtD
Gadoversetamide—Myalgia—Fluorouracil—colon cancer	0.00219	0.00219	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Vincristine—colon cancer	0.00218	0.00218	CcSEcCtD
Gadoversetamide—Epistaxis—Capecitabine—colon cancer	0.00217	0.00217	CcSEcCtD
Gadoversetamide—Discomfort—Fluorouracil—colon cancer	0.00217	0.00217	CcSEcCtD
Gadoversetamide—Shock—Irinotecan—colon cancer	0.00216	0.00216	CcSEcCtD
Gadoversetamide—Nervous system disorder—Irinotecan—colon cancer	0.00215	0.00215	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Irinotecan—colon cancer	0.00215	0.00215	CcSEcCtD
Gadoversetamide—Anorexia—Vincristine—colon cancer	0.00215	0.00215	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Irinotecan—colon cancer	0.00212	0.00212	CcSEcCtD
Gadoversetamide—Confusional state—Fluorouracil—colon cancer	0.00212	0.00212	CcSEcCtD
Gadoversetamide—Hypotension—Vincristine—colon cancer	0.00211	0.00211	CcSEcCtD
Gadoversetamide—Oedema—Fluorouracil—colon cancer	0.0021	0.0021	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Fluorouracil—colon cancer	0.0021	0.0021	CcSEcCtD
Gadoversetamide—Anorexia—Irinotecan—colon cancer	0.00209	0.00209	CcSEcCtD
Gadoversetamide—Haemoglobin—Capecitabine—colon cancer	0.00208	0.00208	CcSEcCtD
Gadoversetamide—Rhinitis—Capecitabine—colon cancer	0.00207	0.00207	CcSEcCtD
Gadoversetamide—Haemorrhage—Capecitabine—colon cancer	0.00207	0.00207	CcSEcCtD
Gadoversetamide—Nervous system disorder—Fluorouracil—colon cancer	0.00206	0.00206	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Fluorouracil—colon cancer	0.00206	0.00206	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Capecitabine—colon cancer	0.00206	0.00206	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Vincristine—colon cancer	0.00205	0.00205	CcSEcCtD
Gadoversetamide—Pharyngitis—Capecitabine—colon cancer	0.00205	0.00205	CcSEcCtD
Gadoversetamide—Tachycardia—Fluorouracil—colon cancer	0.00205	0.00205	CcSEcCtD
Gadoversetamide—Hypotension—Irinotecan—colon cancer	0.00205	0.00205	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Capecitabine—colon cancer	0.00204	0.00204	CcSEcCtD
Gadoversetamide—Insomnia—Vincristine—colon cancer	0.00204	0.00204	CcSEcCtD
Gadoversetamide—Oedema peripheral—Capecitabine—colon cancer	0.00204	0.00204	CcSEcCtD
Gadoversetamide—Urethral disorder—Capecitabine—colon cancer	0.00203	0.00203	CcSEcCtD
Gadoversetamide—Paraesthesia—Vincristine—colon cancer	0.00202	0.00202	CcSEcCtD
Gadoversetamide—Anorexia—Fluorouracil—colon cancer	0.002	0.002	CcSEcCtD
Gadoversetamide—Insomnia—Irinotecan—colon cancer	0.00199	0.00199	CcSEcCtD
Gadoversetamide—Paraesthesia—Irinotecan—colon cancer	0.00197	0.00197	CcSEcCtD
Gadoversetamide—Hypotension—Fluorouracil—colon cancer	0.00196	0.00196	CcSEcCtD
Gadoversetamide—Decreased appetite—Vincristine—colon cancer	0.00196	0.00196	CcSEcCtD
Gadoversetamide—Dyspnoea—Irinotecan—colon cancer	0.00196	0.00196	CcSEcCtD
Gadoversetamide—Erythema multiforme—Capecitabine—colon cancer	0.00196	0.00196	CcSEcCtD
Gadoversetamide—Somnolence—Irinotecan—colon cancer	0.00195	0.00195	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Vincristine—colon cancer	0.00195	0.00195	CcSEcCtD
Gadoversetamide—Fatigue—Vincristine—colon cancer	0.00194	0.00194	CcSEcCtD
Gadoversetamide—Eye disorder—Capecitabine—colon cancer	0.00193	0.00193	CcSEcCtD
Gadoversetamide—Dyspepsia—Irinotecan—colon cancer	0.00193	0.00193	CcSEcCtD
Gadoversetamide—Tinnitus—Capecitabine—colon cancer	0.00193	0.00193	CcSEcCtD
Gadoversetamide—Pain—Vincristine—colon cancer	0.00193	0.00193	CcSEcCtD
Gadoversetamide—Constipation—Vincristine—colon cancer	0.00193	0.00193	CcSEcCtD
Gadoversetamide—Asthma—Methotrexate—colon cancer	0.00192	0.00192	CcSEcCtD
Gadoversetamide—Flushing—Capecitabine—colon cancer	0.00192	0.00192	CcSEcCtD
Gadoversetamide—Cardiac disorder—Capecitabine—colon cancer	0.00192	0.00192	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00192	0.00192	CcSEcCtD
Gadoversetamide—Decreased appetite—Irinotecan—colon cancer	0.00191	0.00191	CcSEcCtD
Gadoversetamide—Insomnia—Fluorouracil—colon cancer	0.0019	0.0019	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Irinotecan—colon cancer	0.0019	0.0019	CcSEcCtD
Gadoversetamide—Fatigue—Irinotecan—colon cancer	0.00189	0.00189	CcSEcCtD
Gadoversetamide—Paraesthesia—Fluorouracil—colon cancer	0.00189	0.00189	CcSEcCtD
Gadoversetamide—Constipation—Irinotecan—colon cancer	0.00188	0.00188	CcSEcCtD
Gadoversetamide—Pain—Irinotecan—colon cancer	0.00188	0.00188	CcSEcCtD
Gadoversetamide—Angiopathy—Capecitabine—colon cancer	0.00188	0.00188	CcSEcCtD
Gadoversetamide—Dyspnoea—Fluorouracil—colon cancer	0.00187	0.00187	CcSEcCtD
Gadoversetamide—Somnolence—Fluorouracil—colon cancer	0.00187	0.00187	CcSEcCtD
Gadoversetamide—Immune system disorder—Capecitabine—colon cancer	0.00187	0.00187	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Capecitabine—colon cancer	0.00186	0.00186	CcSEcCtD
Gadoversetamide—Chills—Capecitabine—colon cancer	0.00186	0.00186	CcSEcCtD
Gadoversetamide—Dyspepsia—Fluorouracil—colon cancer	0.00185	0.00185	CcSEcCtD
Gadoversetamide—Arrhythmia—Capecitabine—colon cancer	0.00185	0.00185	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Vincristine—colon cancer	0.00184	0.00184	CcSEcCtD
Gadoversetamide—Decreased appetite—Fluorouracil—colon cancer	0.00183	0.00183	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00181	0.00181	CcSEcCtD
Gadoversetamide—Mental disorder—Capecitabine—colon cancer	0.00181	0.00181	CcSEcCtD
Gadoversetamide—Feeling abnormal—Irinotecan—colon cancer	0.00181	0.00181	CcSEcCtD
Gadoversetamide—Malnutrition—Capecitabine—colon cancer	0.0018	0.0018	CcSEcCtD
Gadoversetamide—Erythema—Capecitabine—colon cancer	0.0018	0.0018	CcSEcCtD
Gadoversetamide—Dysuria—Methotrexate—colon cancer	0.0018	0.0018	CcSEcCtD
Gadoversetamide—Pain—Fluorouracil—colon cancer	0.0018	0.0018	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Irinotecan—colon cancer	0.00179	0.00179	CcSEcCtD
Gadoversetamide—Body temperature increased—Vincristine—colon cancer	0.00178	0.00178	CcSEcCtD
Gadoversetamide—Abdominal pain—Vincristine—colon cancer	0.00178	0.00178	CcSEcCtD
Gadoversetamide—Flatulence—Capecitabine—colon cancer	0.00177	0.00177	CcSEcCtD
Gadoversetamide—Dysgeusia—Capecitabine—colon cancer	0.00176	0.00176	CcSEcCtD
Gadoversetamide—Back pain—Capecitabine—colon cancer	0.00174	0.00174	CcSEcCtD
Gadoversetamide—Abdominal pain—Irinotecan—colon cancer	0.00174	0.00174	CcSEcCtD
Gadoversetamide—Body temperature increased—Irinotecan—colon cancer	0.00174	0.00174	CcSEcCtD
Gadoversetamide—Feeling abnormal—Fluorouracil—colon cancer	0.00173	0.00173	CcSEcCtD
Gadoversetamide—Muscle spasms—Capecitabine—colon cancer	0.00173	0.00173	CcSEcCtD
Gadoversetamide—Pneumonia—Methotrexate—colon cancer	0.00172	0.00172	CcSEcCtD
Gadoversetamide—Vision blurred—Capecitabine—colon cancer	0.0017	0.0017	CcSEcCtD
Gadoversetamide—Tremor—Capecitabine—colon cancer	0.00169	0.00169	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Capecitabine—colon cancer	0.00167	0.00167	CcSEcCtD
Gadoversetamide—Urticaria—Fluorouracil—colon cancer	0.00167	0.00167	CcSEcCtD
Gadoversetamide—Conjunctivitis—Methotrexate—colon cancer	0.00167	0.00167	CcSEcCtD
Gadoversetamide—Body temperature increased—Fluorouracil—colon cancer	0.00166	0.00166	CcSEcCtD
Gadoversetamide—Hypersensitivity—Vincristine—colon cancer	0.00166	0.00166	CcSEcCtD
Gadoversetamide—Haematuria—Methotrexate—colon cancer	0.00163	0.00163	CcSEcCtD
Gadoversetamide—Malaise—Capecitabine—colon cancer	0.00162	0.00162	CcSEcCtD
Gadoversetamide—Epistaxis—Methotrexate—colon cancer	0.00162	0.00162	CcSEcCtD
Gadoversetamide—Vertigo—Capecitabine—colon cancer	0.00162	0.00162	CcSEcCtD
Gadoversetamide—Hypersensitivity—Irinotecan—colon cancer	0.00162	0.00162	CcSEcCtD
Gadoversetamide—Asthenia—Vincristine—colon cancer	0.00162	0.00162	CcSEcCtD
Gadoversetamide—Syncope—Capecitabine—colon cancer	0.00161	0.00161	CcSEcCtD
Gadoversetamide—Palpitations—Capecitabine—colon cancer	0.00159	0.00159	CcSEcCtD
Gadoversetamide—Loss of consciousness—Capecitabine—colon cancer	0.00158	0.00158	CcSEcCtD
Gadoversetamide—Asthenia—Irinotecan—colon cancer	0.00157	0.00157	CcSEcCtD
Gadoversetamide—Cough—Capecitabine—colon cancer	0.00157	0.00157	CcSEcCtD
Gadoversetamide—Hypertension—Capecitabine—colon cancer	0.00155	0.00155	CcSEcCtD
Gadoversetamide—Hypersensitivity—Fluorouracil—colon cancer	0.00155	0.00155	CcSEcCtD
Gadoversetamide—Haemoglobin—Methotrexate—colon cancer	0.00155	0.00155	CcSEcCtD
Gadoversetamide—Diarrhoea—Vincristine—colon cancer	0.00154	0.00154	CcSEcCtD
Gadoversetamide—Haemorrhage—Methotrexate—colon cancer	0.00154	0.00154	CcSEcCtD
Gadoversetamide—Arthralgia—Capecitabine—colon cancer	0.00153	0.00153	CcSEcCtD
Gadoversetamide—Chest pain—Capecitabine—colon cancer	0.00153	0.00153	CcSEcCtD
Gadoversetamide—Myalgia—Capecitabine—colon cancer	0.00153	0.00153	CcSEcCtD
Gadoversetamide—Pharyngitis—Methotrexate—colon cancer	0.00153	0.00153	CcSEcCtD
Gadoversetamide—Anxiety—Capecitabine—colon cancer	0.00153	0.00153	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00152	0.00152	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Methotrexate—colon cancer	0.00152	0.00152	CcSEcCtD
Gadoversetamide—Discomfort—Capecitabine—colon cancer	0.00151	0.00151	CcSEcCtD
Gadoversetamide—Urethral disorder—Methotrexate—colon cancer	0.00151	0.00151	CcSEcCtD
Gadoversetamide—Diarrhoea—Irinotecan—colon cancer	0.0015	0.0015	CcSEcCtD
Gadoversetamide—Dry mouth—Capecitabine—colon cancer	0.0015	0.0015	CcSEcCtD
Gadoversetamide—Dizziness—Vincristine—colon cancer	0.00149	0.00149	CcSEcCtD
Gadoversetamide—Pruritus—Fluorouracil—colon cancer	0.00149	0.00149	CcSEcCtD
Gadoversetamide—Confusional state—Capecitabine—colon cancer	0.00148	0.00148	CcSEcCtD
Gadoversetamide—Oedema—Capecitabine—colon cancer	0.00147	0.00147	CcSEcCtD
Gadoversetamide—Erythema multiforme—Methotrexate—colon cancer	0.00146	0.00146	CcSEcCtD
Gadoversetamide—Dizziness—Irinotecan—colon cancer	0.00145	0.00145	CcSEcCtD
Gadoversetamide—Shock—Capecitabine—colon cancer	0.00145	0.00145	CcSEcCtD
Gadoversetamide—Nervous system disorder—Capecitabine—colon cancer	0.00144	0.00144	CcSEcCtD
Gadoversetamide—Eye disorder—Methotrexate—colon cancer	0.00144	0.00144	CcSEcCtD
Gadoversetamide—Diarrhoea—Fluorouracil—colon cancer	0.00144	0.00144	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Capecitabine—colon cancer	0.00144	0.00144	CcSEcCtD
Gadoversetamide—Tinnitus—Methotrexate—colon cancer	0.00144	0.00144	CcSEcCtD
Gadoversetamide—Tachycardia—Capecitabine—colon cancer	0.00143	0.00143	CcSEcCtD
Gadoversetamide—Vomiting—Vincristine—colon cancer	0.00143	0.00143	CcSEcCtD
Gadoversetamide—Cardiac disorder—Methotrexate—colon cancer	0.00143	0.00143	CcSEcCtD
Gadoversetamide—Skin disorder—Capecitabine—colon cancer	0.00143	0.00143	CcSEcCtD
Gadoversetamide—Rash—Vincristine—colon cancer	0.00142	0.00142	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Capecitabine—colon cancer	0.00142	0.00142	CcSEcCtD
Gadoversetamide—Dermatitis—Vincristine—colon cancer	0.00142	0.00142	CcSEcCtD
Gadoversetamide—Headache—Vincristine—colon cancer	0.00141	0.00141	CcSEcCtD
Gadoversetamide—Anorexia—Capecitabine—colon cancer	0.0014	0.0014	CcSEcCtD
Gadoversetamide—Angiopathy—Methotrexate—colon cancer	0.0014	0.0014	CcSEcCtD
Gadoversetamide—Vomiting—Irinotecan—colon cancer	0.0014	0.0014	CcSEcCtD
Gadoversetamide—Immune system disorder—Methotrexate—colon cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Dizziness—Fluorouracil—colon cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Methotrexate—colon cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Rash—Irinotecan—colon cancer	0.00138	0.00138	CcSEcCtD
Gadoversetamide—Dermatitis—Irinotecan—colon cancer	0.00138	0.00138	CcSEcCtD
Gadoversetamide—Chills—Methotrexate—colon cancer	0.00138	0.00138	CcSEcCtD
Gadoversetamide—Headache—Irinotecan—colon cancer	0.00138	0.00138	CcSEcCtD
Gadoversetamide—Hypotension—Capecitabine—colon cancer	0.00137	0.00137	CcSEcCtD
Gadoversetamide—Mental disorder—Methotrexate—colon cancer	0.00135	0.00135	CcSEcCtD
Gadoversetamide—Erythema—Methotrexate—colon cancer	0.00134	0.00134	CcSEcCtD
Gadoversetamide—Malnutrition—Methotrexate—colon cancer	0.00134	0.00134	CcSEcCtD
Gadoversetamide—Nausea—Vincristine—colon cancer	0.00134	0.00134	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00134	0.00134	CcSEcCtD
Gadoversetamide—Vomiting—Fluorouracil—colon cancer	0.00134	0.00134	CcSEcCtD
Gadoversetamide—Insomnia—Capecitabine—colon cancer	0.00133	0.00133	CcSEcCtD
Gadoversetamide—Rash—Fluorouracil—colon cancer	0.00133	0.00133	CcSEcCtD
Gadoversetamide—Dermatitis—Fluorouracil—colon cancer	0.00132	0.00132	CcSEcCtD
Gadoversetamide—Paraesthesia—Capecitabine—colon cancer	0.00132	0.00132	CcSEcCtD
Gadoversetamide—Headache—Fluorouracil—colon cancer	0.00132	0.00132	CcSEcCtD
Gadoversetamide—Dysgeusia—Methotrexate—colon cancer	0.00131	0.00131	CcSEcCtD
Gadoversetamide—Dyspnoea—Capecitabine—colon cancer	0.00131	0.00131	CcSEcCtD
Gadoversetamide—Nausea—Irinotecan—colon cancer	0.0013	0.0013	CcSEcCtD
Gadoversetamide—Back pain—Methotrexate—colon cancer	0.0013	0.0013	CcSEcCtD
Gadoversetamide—Dyspepsia—Capecitabine—colon cancer	0.00129	0.00129	CcSEcCtD
Gadoversetamide—Decreased appetite—Capecitabine—colon cancer	0.00128	0.00128	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Capecitabine—colon cancer	0.00127	0.00127	CcSEcCtD
Gadoversetamide—Fatigue—Capecitabine—colon cancer	0.00127	0.00127	CcSEcCtD
Gadoversetamide—Vision blurred—Methotrexate—colon cancer	0.00126	0.00126	CcSEcCtD
Gadoversetamide—Pain—Capecitabine—colon cancer	0.00126	0.00126	CcSEcCtD
Gadoversetamide—Constipation—Capecitabine—colon cancer	0.00126	0.00126	CcSEcCtD
Gadoversetamide—Nausea—Fluorouracil—colon cancer	0.00125	0.00125	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Methotrexate—colon cancer	0.00124	0.00124	CcSEcCtD
Gadoversetamide—Feeling abnormal—Capecitabine—colon cancer	0.00121	0.00121	CcSEcCtD
Gadoversetamide—Malaise—Methotrexate—colon cancer	0.00121	0.00121	CcSEcCtD
Gadoversetamide—Vertigo—Methotrexate—colon cancer	0.0012	0.0012	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Capecitabine—colon cancer	0.0012	0.0012	CcSEcCtD
Gadoversetamide—Cough—Methotrexate—colon cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Urticaria—Capecitabine—colon cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Abdominal pain—Capecitabine—colon cancer	0.00116	0.00116	CcSEcCtD
Gadoversetamide—Body temperature increased—Capecitabine—colon cancer	0.00116	0.00116	CcSEcCtD
Gadoversetamide—Convulsion—Methotrexate—colon cancer	0.00116	0.00116	CcSEcCtD
Gadoversetamide—Chest pain—Methotrexate—colon cancer	0.00114	0.00114	CcSEcCtD
Gadoversetamide—Myalgia—Methotrexate—colon cancer	0.00114	0.00114	CcSEcCtD
Gadoversetamide—Arthralgia—Methotrexate—colon cancer	0.00114	0.00114	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Discomfort—Methotrexate—colon cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Confusional state—Methotrexate—colon cancer	0.0011	0.0011	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Methotrexate—colon cancer	0.00109	0.00109	CcSEcCtD
Gadoversetamide—Hypersensitivity—Capecitabine—colon cancer	0.00108	0.00108	CcSEcCtD
Gadoversetamide—Nervous system disorder—Methotrexate—colon cancer	0.00107	0.00107	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Methotrexate—colon cancer	0.00107	0.00107	CcSEcCtD
Gadoversetamide—Skin disorder—Methotrexate—colon cancer	0.00106	0.00106	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Methotrexate—colon cancer	0.00106	0.00106	CcSEcCtD
Gadoversetamide—Asthenia—Capecitabine—colon cancer	0.00105	0.00105	CcSEcCtD
Gadoversetamide—Anorexia—Methotrexate—colon cancer	0.00104	0.00104	CcSEcCtD
Gadoversetamide—Pruritus—Capecitabine—colon cancer	0.00104	0.00104	CcSEcCtD
Gadoversetamide—Hypotension—Methotrexate—colon cancer	0.00102	0.00102	CcSEcCtD
Gadoversetamide—Diarrhoea—Capecitabine—colon cancer	0.00101	0.00101	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000996	0.000996	CcSEcCtD
Gadoversetamide—Insomnia—Methotrexate—colon cancer	0.000989	0.000989	CcSEcCtD
Gadoversetamide—Paraesthesia—Methotrexate—colon cancer	0.000982	0.000982	CcSEcCtD
Gadoversetamide—Dyspnoea—Methotrexate—colon cancer	0.000975	0.000975	CcSEcCtD
Gadoversetamide—Somnolence—Methotrexate—colon cancer	0.000972	0.000972	CcSEcCtD
Gadoversetamide—Dizziness—Capecitabine—colon cancer	0.000971	0.000971	CcSEcCtD
Gadoversetamide—Dyspepsia—Methotrexate—colon cancer	0.000963	0.000963	CcSEcCtD
Gadoversetamide—Decreased appetite—Methotrexate—colon cancer	0.000951	0.000951	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Methotrexate—colon cancer	0.000944	0.000944	CcSEcCtD
Gadoversetamide—Fatigue—Methotrexate—colon cancer	0.000943	0.000943	CcSEcCtD
Gadoversetamide—Pain—Methotrexate—colon cancer	0.000935	0.000935	CcSEcCtD
Gadoversetamide—Vomiting—Capecitabine—colon cancer	0.000934	0.000934	CcSEcCtD
Gadoversetamide—Rash—Capecitabine—colon cancer	0.000926	0.000926	CcSEcCtD
Gadoversetamide—Dermatitis—Capecitabine—colon cancer	0.000925	0.000925	CcSEcCtD
Gadoversetamide—Headache—Capecitabine—colon cancer	0.00092	0.00092	CcSEcCtD
Gadoversetamide—Feeling abnormal—Methotrexate—colon cancer	0.000901	0.000901	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Methotrexate—colon cancer	0.000894	0.000894	CcSEcCtD
Gadoversetamide—Nausea—Capecitabine—colon cancer	0.000873	0.000873	CcSEcCtD
Gadoversetamide—Urticaria—Methotrexate—colon cancer	0.000869	0.000869	CcSEcCtD
Gadoversetamide—Abdominal pain—Methotrexate—colon cancer	0.000865	0.000865	CcSEcCtD
Gadoversetamide—Body temperature increased—Methotrexate—colon cancer	0.000865	0.000865	CcSEcCtD
Gadoversetamide—Hypersensitivity—Methotrexate—colon cancer	0.000806	0.000806	CcSEcCtD
Gadoversetamide—Asthenia—Methotrexate—colon cancer	0.000785	0.000785	CcSEcCtD
Gadoversetamide—Pruritus—Methotrexate—colon cancer	0.000774	0.000774	CcSEcCtD
Gadoversetamide—Diarrhoea—Methotrexate—colon cancer	0.000748	0.000748	CcSEcCtD
Gadoversetamide—Dizziness—Methotrexate—colon cancer	0.000723	0.000723	CcSEcCtD
Gadoversetamide—Vomiting—Methotrexate—colon cancer	0.000695	0.000695	CcSEcCtD
Gadoversetamide—Rash—Methotrexate—colon cancer	0.00069	0.00069	CcSEcCtD
Gadoversetamide—Dermatitis—Methotrexate—colon cancer	0.000689	0.000689	CcSEcCtD
Gadoversetamide—Headache—Methotrexate—colon cancer	0.000685	0.000685	CcSEcCtD
Gadoversetamide—Nausea—Methotrexate—colon cancer	0.00065	0.00065	CcSEcCtD
